A GenAI copilot for biopharma regulatory requirements could yield significant returns.
RegASK, a regulatory intelligence company, has released an AI-based conversational copilot to provide regulatory information tailored to the organization’s specific context.
The new offering, RegGenius, could prove invaluable to biopharma companies navigating recent and upcoming changes to regulatory requirements for everything...
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
